Go to Health Care Provider version
| Diagnosis | CD22+ Leukemia or Lymphoma | Study Status | Open |
| Phase | I/II |
| Age | up to 30 Years | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Biological: SCRI-CAR22v2 (Single infusion) |
| Last Posted Update | 2025-07-16 |
| ClinicalTrials.gov # | NCT04571138 |
International Sponsor
Seattle Children's HospitalPrincipal Investigators for Canadian Sites
BC Children's Hospital - Dr. Amanda LiCentres
Medical contact
Rebecca Deyell
Social worker/patient navigator contact
Ilana Katz
Clinical research contact
Hem/Onc/BMT Clinical Trials Unit
Study Description
This study is for people with leukemia or lymphoma that didn’t get better with treatment or came back. Doctors will take the patient’s own immune cells (T cells), change them in the lab to help them find and kill cancer, and give them back to the patient. These are called CAR T cells.
The CAR T cells in this study look for a cancer marker called CD22.
- The first part of the study checks if the treatment is safe and finds the right dose.
- The second part checks if this treatment is effective.
Inclusion Criteria
- Participants must be 30 years or younger
- Participants must have leukemia or lymphoma that has come back or not responded to treatment
- Participants must be able to have blood collected or have enough T cells stored
- Must be up and about at least 50% of waking hours
- Recovered from side effects of past treatments if using new T cells
- Must meet organ function and blood test requirements
- If participant can have children, a strong birth control must be used until 12 months after treatment
- Participant or legal guardian must sign consent form
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
